CD274 and head and neck squamous cell carcinoma: This phase III study evaluated the efficacy of pembrolizumab (anti-PD-1) alone and in combination with cisplatin/carboplatin plus 5FU vs. the EXTREME regimen as first-line therapy for R/M-HNSCC based on PD-L1 expression by CPS (combined positive score) (15).